JP7055740B2 - 多能性幹細胞由来膵前駆細胞の純化法とその増幅法 - Google Patents
多能性幹細胞由来膵前駆細胞の純化法とその増幅法 Download PDFInfo
- Publication number
- JP7055740B2 JP7055740B2 JP2018514702A JP2018514702A JP7055740B2 JP 7055740 B2 JP7055740 B2 JP 7055740B2 JP 2018514702 A JP2018514702 A JP 2018514702A JP 2018514702 A JP2018514702 A JP 2018514702A JP 7055740 B2 JP7055740 B2 JP 7055740B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pancreatic progenitor
- progenitor cells
- culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 199
- 238000000034 method Methods 0.000 title claims description 86
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims description 70
- 230000003321 amplification Effects 0.000 title description 10
- 238000003199 nucleic acid amplification method Methods 0.000 title description 10
- 238000000746 purification Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 266
- 239000002609 medium Substances 0.000 claims description 96
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 53
- 210000004153 islets of langerhan Anatomy 0.000 claims description 41
- 230000004069 differentiation Effects 0.000 claims description 39
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 32
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 32
- 238000012258 culturing Methods 0.000 claims description 32
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 32
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 29
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 28
- 238000012136 culture method Methods 0.000 claims description 26
- 102100022762 R-spondin-1 Human genes 0.000 claims description 16
- 101000825954 Homo sapiens R-spondin-1 Proteins 0.000 claims description 15
- 238000005138 cryopreservation Methods 0.000 claims description 15
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000007710 freezing Methods 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000004114 suspension culture Methods 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 230000008472 epithelial growth Effects 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 49
- 101800003838 Epidermal growth factor Proteins 0.000 description 49
- 229940116977 epidermal growth factor Drugs 0.000 description 49
- 239000003112 inhibitor Substances 0.000 description 43
- 229920000936 Agarose Polymers 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 19
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 15
- 239000002771 cell marker Substances 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 102000038624 GSKs Human genes 0.000 description 14
- 108091007911 GSKs Proteins 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 102000013814 Wnt Human genes 0.000 description 14
- 108050003627 Wnt Proteins 0.000 description 14
- 230000002062 proliferating effect Effects 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 12
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 235000013861 fat-free Nutrition 0.000 description 11
- 239000011435 rock Substances 0.000 description 11
- 239000013589 supplement Substances 0.000 description 11
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 108010075254 C-Peptide Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000000853 adhesive Substances 0.000 description 10
- 230000001070 adhesive effect Effects 0.000 description 10
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 description 9
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 102000041829 R-spondin family Human genes 0.000 description 9
- 108091078718 R-spondin family Proteins 0.000 description 9
- -1 Wnt-3a Proteins 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 229930002330 retinoic acid Natural products 0.000 description 9
- 229960001727 tretinoin Drugs 0.000 description 9
- FOORCIAZMIWALX-ULJHMMPZSA-N (z)-n-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenylpyrazol-4-yl)methanimine Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1\C=N/N(CC1)CCN1CC1=CC=CC=C1 FOORCIAZMIWALX-ULJHMMPZSA-N 0.000 description 8
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 description 8
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 8
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 description 8
- 210000003890 endocrine cell Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108091005735 TGF-beta receptors Proteins 0.000 description 6
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 6
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 6
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 102000005157 Somatostatin Human genes 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000013028 medium composition Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 5
- 229960000553 somatostatin Drugs 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 230000036962 time dependent Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 4
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 4
- 108050002062 Fibroblast growth factor 22 Proteins 0.000 description 4
- 102100024804 Fibroblast growth factor 22 Human genes 0.000 description 4
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 4
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 4
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
- 108090000031 Hedgehog Proteins Proteins 0.000 description 4
- 102000003693 Hedgehog Proteins Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000603702 Homo sapiens Neurogenin-3 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100038553 Neurogenin-3 Human genes 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 3
- RCKYSTKYIVULEK-UHFFFAOYSA-N 2-methyl-5-[3-(4-methylsulfinylphenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C1=CC=C(OC=C2C=3C=CC(=CC=3)S(C)=O)C2=C1 RCKYSTKYIVULEK-UHFFFAOYSA-N 0.000 description 3
- 102000007299 Amphiregulin Human genes 0.000 description 3
- 108010033760 Amphiregulin Proteins 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 101800001382 Betacellulin Proteins 0.000 description 3
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 3
- 101100264044 Caenorhabditis elegans cwn-2 gene Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101100317380 Danio rerio wnt4a gene Proteins 0.000 description 3
- 101100428956 Danio rerio wnt8b gene Proteins 0.000 description 3
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 3
- 101000855004 Homo sapiens Protein Wnt-7a Proteins 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 3
- ACXGELCLQKZFMQ-UHFFFAOYSA-N ONC(C1=CC=C(C=C1)CN1C=C(C2=CC=CC=C12)CCO)=O Chemical compound ONC(C1=CC=C(C=C1)CN1C=C(C2=CC=CC=C12)CCO)=O ACXGELCLQKZFMQ-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102100029837 Probetacellulin Human genes 0.000 description 3
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 3
- 102100020729 Protein Wnt-7a Human genes 0.000 description 3
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 101150010310 WNT-4 gene Proteins 0.000 description 3
- 101150019524 WNT2 gene Proteins 0.000 description 3
- 102000052547 Wnt-1 Human genes 0.000 description 3
- 108700020987 Wnt-1 Proteins 0.000 description 3
- 108700020986 Wnt-2 Proteins 0.000 description 3
- 102000052556 Wnt-2 Human genes 0.000 description 3
- 102000052549 Wnt-3 Human genes 0.000 description 3
- 108700020985 Wnt-3 Proteins 0.000 description 3
- 102000052548 Wnt-4 Human genes 0.000 description 3
- 108700020984 Wnt-4 Proteins 0.000 description 3
- 101000770767 Xenopus laevis Protein Wnt-2b-A Proteins 0.000 description 3
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 description 3
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002907 exocrine cell Anatomy 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- HBDSHCUSXQATPO-BGBJRWHRSA-N indirubin-3'-monoxime Chemical compound O=C/1NC2=CC=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 HBDSHCUSXQATPO-BGBJRWHRSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- JYCNWQGNEJYDQS-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine Chemical compound C1=C(Cl)C(C)=CC=C1NC1=NN=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 JYCNWQGNEJYDQS-UHFFFAOYSA-N 0.000 description 3
- 230000015031 pancreas development Effects 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 2
- DWHVZCLBMTZRQM-UHFFFAOYSA-N 2H-pyrazolo[4,3-b]quinoxalin-3-amine Chemical compound C1=CC=CC2=NC3=C(N)NN=C3N=C21 DWHVZCLBMTZRQM-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100029087 Hepatocyte nuclear factor 6 Human genes 0.000 description 2
- 102100027886 Homeobox protein Nkx-2.2 Human genes 0.000 description 2
- 101000988619 Homo sapiens Hepatocyte nuclear factor 6 Proteins 0.000 description 2
- 101000632186 Homo sapiens Homeobox protein Nkx-2.2 Proteins 0.000 description 2
- 101000576323 Homo sapiens Motor neuron and pancreas homeobox protein 1 Proteins 0.000 description 2
- 101000613495 Homo sapiens Paired box protein Pax-4 Proteins 0.000 description 2
- 101000825949 Homo sapiens R-spondin-2 Proteins 0.000 description 2
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 2
- 101000825962 Homo sapiens R-spondin-4 Proteins 0.000 description 2
- 102100025170 Motor neuron and pancreas homeobox protein 1 Human genes 0.000 description 2
- 101100485095 Mus musculus Wnt10b gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100040909 Paired box protein Pax-4 Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102100022763 R-spondin-2 Human genes 0.000 description 2
- 102100022766 R-spondin-3 Human genes 0.000 description 2
- 102100022759 R-spondin-4 Human genes 0.000 description 2
- 102100036428 Spondin-1 Human genes 0.000 description 2
- 101710092167 Spondin-1 Proteins 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940098448 fibroblast growth factor 7 Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- WDHRPWOAMDJICD-FOAQWNCLSA-N n-[2-[(3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide Chemical compound C([C@@H](C)C[C@@H]1[C@@H]2[C@H]([C@]3(C(=C4C[C@@H]5[C@@]6(C)CCC(=O)CC6=CC[C@H]5[C@@H]4CC3)C)O1)C)N2CCNC(=O)CCCCCNC(=O)CCC1=CC=CC=C1 WDHRPWOAMDJICD-FOAQWNCLSA-N 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- WOLVEMPZUIFSII-IHHOKICGSA-N (2e,4e)-n-[(2s,5s)-5-(hydroxymethyl)-1-methyl-3-oxo-2-propan-2-yl-2,4,5,6-tetrahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]penta-2,4-dienamide Chemical compound CN([C@H](C(N[C@H](CO)CC1=C2)=O)C(C)C)C1=CC=C2NC(=O)\C=C\C=C\C1=CC=C(C(F)(F)F)C=C1 WOLVEMPZUIFSII-IHHOKICGSA-N 0.000 description 1
- QSHGISMANBKLQL-OWJWWREXSA-N (2s)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-n-[(7s)-5-methyl-6-oxo-7h-benzo[d][1]benzazepin-7-yl]propanamide Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C2=CC=CC=C21)=O)C(=O)CC1=CC(F)=CC(F)=C1 QSHGISMANBKLQL-OWJWWREXSA-N 0.000 description 1
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150099612 Esrrb gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- CLEXYFLHGFJONT-DNMILWOZSA-N Jervine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](C(=O)C2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C CLEXYFLHGFJONT-DNMILWOZSA-N 0.000 description 1
- 101150072501 Klf2 gene Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150072008 NR5A2 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100025036 Norrin Human genes 0.000 description 1
- 101710085992 Norrin Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101710110302 R-spondin-1 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 101150111019 Tbx3 gene Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003306 cell dissemination Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000011977 dual antiplatelet therapy Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- CLEXYFLHGFJONT-UHFFFAOYSA-N jervine Natural products C1C=C2CC(O)CCC2(C)C(C(=O)C2=C3C)C1C2CCC13OC2CC(C)CNC2C1C CLEXYFLHGFJONT-UHFFFAOYSA-N 0.000 description 1
- QRXOCOSLDOPPKH-UHFFFAOYSA-N jervine sulfate Natural products CC1CNC2C(C1)OC3(CCC4=C(C3C)C(=O)C5C4CC=C6CC(O)CCC56C)C2C QRXOCOSLDOPPKH-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- BQJRUJTZSGYBEZ-NQGQECDZSA-N pdbu Chemical compound C([C@@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-NQGQECDZSA-N 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Description
(I-1) 多能性幹細胞由来の膵前駆細胞の培養方法であって、(A)多能性幹細胞由来の膵前駆細胞を(1)上皮成長因子(EGF)ファミリーに属する因子及び/又は線維芽細胞成長因子(FGF)ファミリーに属する因子、並びに(2)Wntアゴニストを含有する培地中で3次元培養する工程を含む、培養方法。
(I-1-A) 前記Wntアゴニストが、Wntファミリーに属する因子、R-スポンジンファミリーに属する因子、ノリン及び/又はGSK阻害剤である、(I-1)に記載の方法。
(I-1-B) 前記Wntアゴニストが、Wnt-1/Int-1、Wnt-2/Irp、Wnt-2b/13、Wnt-3/Int-4、Wnt-3a、Wnt-4、Wnt-5a、Wnt-5b、Wnt-6、Wnt-7a、Wnt-7b、Wnt-8a/8d、Wnt-8b、Wnt-9a/14、Wnt-9b/14b/15、Wnt-10a、Wnt-10b/12、Wnt-11、Wnt-16、CHIR99021、SB216763、SB415286、A1070722、BIO、BIO-acetoxime、Indirubin-3'-oxime、NSC 693868、TC-G 24、TCS 2002、TWS 119、siRNA、リチウム、ケンパウロン、R-スポンジン1、R-スポンジン2、R-スポンジン3、R-スポンジン4、及びノリンからなる群から選択される少なくとも1つの因子を含む、(I-1)に記載の方法。
(I-2) 前記WntアゴニストがR-スポンジンファミリーに属するタンパク質及び/又はGSK阻害剤である、(I-1)に記載の方法。
(I-2-A) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子が、ErbB1に結合する因子及び/又はFGFR2IIIbに結合する因子である、(I-1)、(I-1-A)、(I-1-B)又は(I-2)に記載の方法。
(I-2-B) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子が、EGF、トランスフォーミング成長因子α(TGF-α)、アンフィレギュリン、ヘパリン結合性EGF様成長因子、シュワノーマ由来成長因子、ベータセルリン、ポックスウイルス成長因子、酸性線維芽細胞成長因子(aFGF、FGF-1)、塩基性線維芽細胞成長因子(bFGF、FGF-2)、FGF-3、角質細胞成長因子(KGF、FGF-7)、FGF-10、及びFGF-22からなる群から選択される少なくとも1つの因子を含む、(I-1)、(I-1-A)、(I-1-B)又は(I-2)に記載の方法。
(I-3) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子がEGFであり、前記(2)WntアゴニストがR-スポンジン1である、(I-1)に記載の方法。
(I-4) 前記EGFファミリーに属する因子がEGFであり、前記FGFファミリーに属する因子がFGF-7であり、前記R-スポンジンファミリーに属するタンパク質がR-スポンジン1であり、前記GSK阻害剤がCHIR99021である、(I-2)に記載の方法。
(I-5) 前記培地が無血清培地である、(I-1)~(I-4)のいずれか一項に記載の方法。
(I-6) 前記培養がフィーダー細胞の非存在下での培養である、(I-1)~(I-5)のいずれか一項に記載の方法。
(I-7) 前記多能性幹細胞がiPS細胞又はES細胞である、(I-1)~(I-6)のいずれか一項に記載の方法。
(I-8) 前記多能性幹細胞がヒト由来である、(I-1)~(I-7)のいずれか一項に記載の方法。
(I-9) 前記3次元培養が膵前駆細胞の凝集体の浮遊培養である、(I-1)~(I-8)のいずれか一項に記載の方法。
(I-10) (B)工程(A)において得られた膵前駆細胞を更に継代培養する工程を更に含む、(I-1)~(I-9)のいずれか一項に記載の方法。
(I-11) 膵前駆細胞の純化のために用いられる、(I-1)~(I-10)のいずれか一項に記載の方法。
(I-12) (C)iPS細胞を調製する工程を更に含み、工程(A)において該iPS細胞由来の膵前駆細胞を使用する、(I-1)~(I-11)のいずれか一項に記載の方法。
(I-13) (D)多能性幹細胞を膵前駆細胞に分化誘導する工程を更に含み、工程Aにおいて該膵前駆細胞を使用する、(I-1)~(I-12)のいずれか一項に記載の方法。
(II-1) 多能性幹細胞由来の膵前駆細胞からの膵島細胞の製造方法であって、(E)(I-1)~(I-13)のいずれか一項に記載の方法により培養した膵前駆細胞を膵島細胞に分化誘導する工程を含む、製造方法。
(III-1) 多能性幹細胞由来の膵前駆細胞の凍結保存方法あって、(F)(I-1)~(I-13)のいずれか一項に記載の方法により培養した膵前駆細胞を凍結する工程を含む、凍結保存方法。
(IV-1) (1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子、並びに(2)Wntアゴニストを含有する多能性幹細胞由来の膵前駆細胞の培養用培地。
(IV-1-A) 前記Wntアゴニストが、Wntファミリーに属する因子、R-スポンジンファミリーに属する因子、ノリン及び/又はGSK阻害剤である、(IV-1)に記載の培地。
(IV-1-B) 前記Wntアゴニストが、Wnt-1/Int-1、Wnt-2/Irp、Wnt-2b/13、Wnt-3/Int-4、Wnt-3a、Wnt-4、Wnt-5a、Wnt-5b、Wnt-6、Wnt-7a、Wnt-7b、Wnt-8a/8d、Wnt-8b、Wnt-9a/14、Wnt-9b/14b/15、Wnt-10a、Wnt-10b/12、Wnt-11、Wnt-16、CHIR99021、SB216763、SB415286、A1070722、BIO、BIO-acetoxime、Indirubin-3’-oxime、NSC 693868、TC-G 24、TCS 2002、TWS 119、siRNA、リチウム、ケンパウロン、R-スポンジン1、R-スポンジン2、R-スポンジン3、R-スポンジン4、及びノリンからなる群から選択される少なくとも1つの因子を含む、(IV-1)に記載の培地。
(IV-2) 前記WntアゴニストがR-スポンジンファミリーに属するタンパク質及び/又はGSK阻害剤である、(VI-1)に記載の培地。
(IV-2-A) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子が、ErbB1に結合する因子及び/又はFGFR2IIIbに結合する因子である、(IV-1)、(IV-1-A)、(IV-1-B)又は(IV-2)に記載の培地。
(IV-2-B) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子が、EGF、トランスフォーミング成長因子α(TGF-α)、アンフィレギュリン、ヘパリン結合性EGF様成長因子、シュワノーマ由来成長因子、ベータセルリン、ポックスウイルス成長因子、酸性線維芽細胞成長因子(aFGF、FGF-1)、塩基性線維芽細胞成長因子(bFGF、FGF-2)、FGF-3、角質細胞成長因子(KGF、FGF-7)、FGF-10、及びFGF-22からなる群から選択される少なくとも1つの因子を含む、(IV-1)、(IV-1-A)、(IV-1-B)又は(IV-2)に記載の培地。
(IV-3) 前記(1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子がEGFであり、前記(2)WntアゴニストがR-スポンジン1である、(VI-1)に記載の培地。
(IV-4) 前記EGFファミリーに属する因子がEGFであり、前記FGFファミリーに属する因子がFGF-7であり、前記R-スポンジンファミリーに属するタンパク質がR-スポンジン1であり、前記GSK阻害剤がCHIR99021である、(IV-2)に記載の培地。
(IV-5) 血清を含まない、(IV-1)~(IV-4)のいずれか一項に記載の培地。
(IV-6) フィーダー細胞非存在下での培養用である、(IV-1)~(IV-5)のいずれか一項に記載の培地。
(IV-7) 前記多能性幹細胞がiPS細胞又はES細胞である、(IV-1)~(IV-6)のいずれか一項に記載の培地。
(IV-8) 前記多能性幹細胞がヒト由来である、(IV-1)~(IV-7)のいずれか一項に記載の培地。
(IV-9) Sonic Hedgehogシグナル阻害剤、TGF-β受容体阻害剤及びレチノイン酸からなる群から選択される少なくとも1種を更に含有する、(IV-1)~(IV-8)のいずれか一項に記載の培地。
(IV-10) 膵前駆細胞の純化のために用いられる、(IV-1)~(IV-9)のいずれか一項に記載の培地。
(V-1) 多能性幹細胞由来の膵前駆細胞の培養用培地における、上記(IV-1)~(IV-4)及び(IV-9)のいずれか一項に記載の成分の使用。
(VI-1) 上記(I-1)~(I-13)のいずれか一項に記載の方法で培養された膵前駆細胞を含む医薬。
(VII-1) (1)EGFファミリーに属する因子及び/又はFGFファミリーに属する因子、(2)Wntアゴニスト、並びに5質量%以上、10質量%以上、15質量%以上又は20質量%以上の膵前駆細胞を含む、単離された培養物。
多能性幹細胞とは、三胚葉(内胚葉、中胚葉、及び外胚葉)のいずれにも分化できる能力(多能性:pluripotency)を有し且つ自己複製可能な幹細胞である。多能性幹細胞としては、特に限定されず、例えば、胚性幹(ES)細胞、核移植により得られるクローン胚由来の胚性幹(ntES)細胞、多能性生殖幹細胞(「mGS細胞」)、胚性生殖細胞(「EG細胞」)、人工多能性幹(iPS)細胞等が挙げられる。また、多能性幹細胞の由来生物としては、特に限定されず、例えば、ヒト、サル、マウス、ラット、モルモット、ウサギ、ウシ、ブタ、イヌ、ウマ、ネコ、ヤギ、ヒツジ等の哺乳動物が挙げられる。中でもヒト由来の多能性幹細胞が好ましい。多能性幹細胞は、市販されているもの若しくは所定の機関により分譲されているもの、又は公知の方法に従い製造したものを使用することができる。多能性幹細胞としては、好ましくはES細胞及びiPS細胞を使用できる。
本発明における膵前駆細胞(pancreatic progenitor)は、その後、膵島細胞へと分化していく細胞をいう。膵前駆細胞は、例えば、PDX1 (pancreas duodenal homeobox gene 1)陽性(及びSOX9陽性)であることを指標とすることができる。
本発明における膵島(ランゲルハンス氏島)細胞は、グルカゴンを分泌するα細胞、インスリンを分泌するβ細胞、及びソマトスタチンを分泌するδ細胞の少なくとも1種を含むものであり、好ましくは少なくともβ細胞を含むものである。膵島細胞にα細胞、β細胞、及びδ細胞が含まれることは、例えば、それぞれ、グルカゴン、インスリン又はCペプチド、及びソマトスタチンに対する抗体を用いる免疫染色で確認することができる。β細胞は、Cペプチドに対する抗体を用いた免疫染色で検出することも可能である。β細胞は、ジチゾン染色によっても検出し得る。膵島細胞には、更に、膵臓ポリペプチドを分泌するF細胞及び膵島前駆細胞が含まれていてもよい。
本発明の多能性幹細胞由来の膵前駆細胞の培養方法は、多能性幹細胞由来の膵前駆細胞を(1)上皮成長因子(EGF)ファミリーに属する因子及び/又は線維芽細胞成長因子(FGF)ファミリーに属する因子(以下、成分(1)と称することがある)、並びに(2)Wntアゴニスト(以下、成分(2)と称することがある)を含有する培地中で3次元培養する工程を含むことを特徴とする。
本発明の培養方法の好ましい実施態様では、工程Aにおいて得られた膵前駆細胞を継代培養する工程を更に含む。
本発明の培養方法は、iPS細胞を調製する工程を更に含み得る。
本発明の培養方法は、多能性幹細胞を膵前駆細胞に分化誘導する工程を更に含み得る。
[参考文献1] Rezania A, Bruin JE, Riedel MJ, Mojibian M, Asadi A, Xu J, Gauvin R, Narayan K, Karanu F, O'Neil JJ, Ao Z, Warnock GL, Kieffer TJ. Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes 2012;61:2016-2029.
[参考文献2] Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O'Dwyer S, Quiskamp N, Mojibian M, Albrecht T, Yang YH, Johnson JD, Kieffer TJ. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014;32:1121-1133.
[参考文献3] Hrvatin S, O'Donnell CW, Deng F, Millman JR, Pagliuca FW, DiIorio P, Rezania A, Gifford DK, Melton DA. Differentiated human stem cells resemble fetal, not adult, β cells. Proc Natl Acad Sci U S A. 2014;111:3038-3043
[参考文献4] Pagliuca FW, Millman JR, Gurtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. Generation of functional human pancreatic β cells in vitro. Cell. 2014;159:428-439.
本発明の多能性幹細胞由来の膵前駆細胞からの膵島細胞の製造方法は、上記の方法により培養した膵前駆細胞を膵島細胞に分化誘導する工程を含むことを特徴とする。
本発明の多能性幹細胞由来の膵前駆細胞の凍結保存方法は、上記の方法により培養した膵前駆細胞を凍結する工程を含むことを特徴とする。
マイクロティシューズ社の3D Petri Dishを用い、メーカーのプロトコル(http://www.funakoshi.co.jp/contents/5556)を参考にしてアガロースマイクロウェルを作製した。ウェル直径400μm、256 well/gel-plateの鋳型を使用した。具体的には、以下の手順でアガロースマイクロウェルを作製した。
iPS細胞(253G1、Riken Cell Bankより入手)をGeltrex (Thermo Fisher Scientific)でコートされた培養容器を用い、E8培地(Thermo Fisher Scientific)で3~4日間培養した。70~80%コンフルエントの状態でTrypLE (Thermo Fisher Scientific)を用いて処理し細胞を単一細胞の状態で回収した。細胞を10μMのY-27632 (ROCK阻害剤:和光純薬工業(株))を含むE8培地に懸濁し、上記で調製したポリスチレン製12 well plateのウェルの一つに設置した256ウェルのアガロースマイクロウェルプレートに、平均2500細胞/wellになるように播種した。
第1段階(3日間)
MCDB131 (Thermo Fisher Scientific)+1.5 g/L NaHCO3 (ナカライテスク(株))+0.5% fat-free BSA (和光純薬工業(株))+2 mM GlutaMax (Thermo Fisher Scientific)+10 mM D-グルコース(ナカライテスク(株))+3μM CHIR99021 (Tocris Bioscience)+100 ng/mL Activin A (R&D Systems)(CHIR99021は初日の培地にのみ加えた)
第2段階(2日間)
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+2 mM GlutaMax+10 mM D-グルコース+50 ng/mL線維芽細胞増殖因子7(FGF-7, PeproTech)+0.25 mM アスコルビン酸 (Sigma-Aldrich)
第3段階(2日間)
MCDB131+1.5 g/L NaHCO3+0.5%脂肪酸不含ウシ血清アルブミン(fat-free BSA)+1/200 ITS supplement (Thermo Fisher Scientific)+2 mM GlutaMax+20 mM D-グルコース+50 ng/mL FGF-7+0.25μM SANT-1 (和光純薬工業(株))+0.1μM LDN193189 (和光純薬工業(株))+1μMレチノイン酸 (Sigma-Aldrich)+0.2μM TBP (PKC activator; Catalog No. 565740; EMD Chemicals Inc.)+0.25 mM アスコルビン酸
第4段階(2日間)
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+50 ng/mL FGF-7+0.25μM SANT-1+0.2μM LDN193189+0.1μMレチノイン酸+0.1μM TBP+0.25 mM アスコルビン酸
TBP: (2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino)benzolactam
上記第1段階から第4段階の培養で得られた細胞の凝集塊を細胞分散用酵素液TrypLE (Thermo Fisher Scientific)を用いて、単一細胞に分散した。細胞を10μMのY-27632 (ROCK阻害剤:和光純薬工業(株))を含む下記の培地に懸濁し、12 well plateのウェル上に設置した256ウェルのアガロースマイクロウェルプレートに、1000細胞/ウェルで播種した(1000×256 = 2.56×105/plate)。10分間静置して細胞を底に沈ませた後、アガロースマイクロウェルプレートの周りから下記の培地を添加し、プレートごと培地の中に浸漬させた。その後、37℃、5%CO2の条件で6日間培養した。培地交換は一日おきに行った。
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+50 ng/mL 上皮成長因子(EGF, 和光純薬工業(株))+200 ng/mL r-スポンジン1 (RSPD1, R&D Systems)+0.25μM SANT-1 (和光純薬工業(株))+0.2μM LDN193189(和光純薬工業(株))+0.1μM レチノイン酸(Sigma-Aldrich)
6日おきにアガロースマイクロウェルプレートより細胞凝集体を回収し、単一細胞に分散した後、新たなアガロースマイクロウェルプレートへ播種した。細胞の分散方法、培地組成及び培養条件は上記の[膵前駆細胞の増幅]と同様とした。
6日おきにアガロースマイクロウェルプレートより細胞凝集体を回収し、SOX9及びPDX1陽性の膵前駆細胞を含む単一細胞に分散した後、新たなアガロースマイクロウェルプレートへ播種した。細胞の分散方法、培地組成、及び培養条件は、上記の[膵前駆細胞の増幅]と同様とした。
上記の[膵前駆細胞の増幅]と同様に、6継代増幅培養した後の膵前駆細胞をアガロースウェルプレートへ播種した。播種密度は3000細胞/ウェルとした。下記第1段階~第3段階に示した手順で内分泌細胞への成熟を行った。具体的には、下記のごとく、経時的に培地組成を変化させた。1日おきに培地を吸い出し、新しい培地に交換し、また所定の日に培地組成を変化させた。培地の組成及びそれぞれの培地中での培養日数は、A Rezania et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol. 2014 Nov;32(11):1121-33.の記載に従った。
第1段階(3日間)
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2mM GlutaMax+20 mM D-グルコース+0.25μM SANT-1+0.2μM LDN193189+0.05μMレチノイン酸+1μM T3 (Thyroid hormone, triiodothyronine, Sigma-Aldrich)+10μM Alk5i II (activin receptor-like kinase receptors 5 阻害剤 II, Enzo Life Sciences, Inc.)+10μg/mLヘパリン(ナカライテスク(株))+10μM Zinc Sulfate (Sigma-Aldrich)
第2段階(7日間)
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+0.2μM LDN193189+1μM T3+10μM Alk5i II+10μg/mL ヘパリン+10μM Zinc Sulfate+0.1μM GSi XX (gamma-secretase inhibitor XX, Merck Millipore)
第3段階(7-14日間)
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+1μM T3+10μM Alk5i II+10μg/mL ヘパリン+10μM Zinc Sulfate+1 mM N-Cys (N-acetylcysteine, Sigma-Aldrich)+2μM R428 (Axl阻害剤, Selleckchem)+10μM Trolox (Merck Millipore)
・凍結
上記の[膵前駆細胞の増幅]と同様にして5継代した後、膵前駆細胞を単一細胞に分散させた。市販の凍結保存液(cell banker 2 (日本全薬工業(株))若しくはstem cell banker (日本全薬工業(株)))又は増殖に用いた培養液に10%ジメチルスルホキシドを添加した溶液を用い、緩慢凍結法により細胞を凍結した。具体的には、500μLの凍結保存液に5×105細胞を懸濁し、凍結バイアルに注入した。凍結処理容器(バイセル、日本フリーザー(株))にバイアルを入れ、-80℃で一晩保存した。長期保存の際は、バイアルを液体窒素タンクに移し保存した。
-80℃で1日間、液体窒素の保存タンクに6時間保存した凍結バイアルを37℃の水浴で加温し、急速に解凍した。解凍された細胞懸濁液を10 mLの培養液(MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース)に添加した。遠心分離により上澄みを除去した後、細胞を10μMのY-27632を含む培地(MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+50 ng/mL EGF+200 ng/mL r-スポンジン1+0.25μM SANT-1+0.2μM LDN193189+0.1μM レチノイン酸+10μM Y-27632)に懸濁し、これにトリパンブルー染色液を添加して解凍後の細胞生存率を算出した。
ヒト由来のiPS細胞として454E2株(Riken Cell Bankより入手)、RPChiPS771-2株((株)リプロセル)、及びP11025株(タカラバイオ(株))を使用した。
上記で得られた膵前駆細胞を253G1株と同様に細胞分散用酵素液TrypLE (Thermo Fisher Scientific)を用いて、単一細胞に分散した。細胞を10μMのY-27632 (ROCK阻害剤:和光純薬工業(株))を含む下記の培地に懸濁し、12 well plateのウェル上に設置した256ウェルのアガロースマイクロウェルプレートに、1000細胞/ウェルで播種した(1000×256 = 2.56×105/plate)。10分間静置して細胞を底に沈ませた後、アガロースマイクロウェルプレートの周りから下記の培地を添加し、プレートごと培地の中に浸漬させた。その後、37℃、5%CO2の条件で4日間培養した。培地交換は一日おきに行った。なお、4因子(EGF+RSPD1+FGF-7+CHIR99021)を含む培地に代えて、3因子(EGF+RSPD1+CHIR99021若しくはEGF+RSPD1+FGF-7)又は2因子(FGF-7+CHIR99021)を含む培地を使用した培養も行った。
MCDB131+1.5 g/L NaHCO3+0.5% fat-free BSA+1/200 ITS supplement+2 mM GlutaMax+20 mM D-グルコース+50 ng/mL上皮成長因子(EGF, 和光純薬工業(株))+200 ng/mL r-スポンジン1 (RSPD1, R&D Systems)+0.25μM SANT-1 (和光純薬工業(株))+0.2μM LDN193189 (和光純薬工業(株))+0.1μM レチノイン酸(Sigma-Aldrich)+4.5μM CHIR99021 (Tocris Bioscience)+50 ng/mL線維芽細胞成長因子7(FGF-7, PeproTech)
Claims (11)
- 多能性幹細胞由来の膵前駆細胞の培養方法であって、(A)多能性幹細胞由来の膵前駆細胞を(1)上皮成長因子(EGF)ファミリーに属する因子及び/又は線維芽細胞成長因子(FGF)ファミリーに属する因子、並びに(2)Wntアゴニストを含有する培地中で3次元培養する工程であって、前記3次元培養が膵前駆細胞の凝集体の浮遊培養であり、前記EGFファミリーに属する因子としてEGFを、前記FGFファミリーに属する因子としてFGF-7を、前記WntアゴニストとしてR-スポンジン1及びCHIR99021を含有する、工程を含む、培養方法。
- 前記培地が無血清培地である、請求項1に記載の方法。
- 前記培養がフィーダー細胞の非存在下での培養である、請求項1又は2に記載の方法。
- 前記多能性幹細胞がiPS細胞又はES細胞である、請求項1~3のいずれか一項に記載の方法。
- 前記多能性幹細胞がヒト由来である、請求項1~4のいずれか一項に記載の方法。
- (B)工程Aにおいて得られた膵前駆細胞を継代培養する工程を更に含む、請求項1~5のいずれか一項に記載の方法。
- 膵前駆細胞の純化のために用いられる、請求項1~6のいずれか一項に記載の方法。
- (C)iPS細胞を調製する工程を更に含み、工程Aにおいて該iPS細胞由来の膵前駆細胞を使用する、請求項1~7のいずれか一項に記載の方法。
- (D)多能性幹細胞を膵前駆細胞に分化誘導する工程を更に含み、工程Aにおいて該膵前駆細胞を使用する、請求項1~8のいずれか一項に記載の方法。
- 多能性幹細胞由来の膵前駆細胞からの膵島細胞の製造方法であって、
(A)多能性幹細胞由来の膵前駆細胞を(1)上皮成長因子(EGF)ファミリーに属する因子及び/又は線維芽細胞成長因子(FGF)ファミリーに属する因子、並びに(2)Wntアゴニストを含有する培地中で3次元培養する工程であって、前記3次元培養が膵前駆細胞の凝集体の浮遊培養であり、前記EGFファミリーに属する因子としてEGFを、前記FGFファミリーに属する因子としてFGF-7を、前記WntアゴニストとしてR-スポンジン1及びCHIR99021を含有する、工程、及び
(E)前記工程により培養した膵前駆細胞を膵島細胞に分化誘導する工程を含む、製造方法。 - 多能性幹細胞由来の膵前駆細胞の凍結保存方法あって、
(A)多能性幹細胞由来の膵前駆細胞を(1)上皮成長因子(EGF)ファミリーに属する因子及び/又は線維芽細胞成長因子(FGF)ファミリーに属する因子、並びに(2)Wntアゴニストを含有する培地中で3次元培養する工程であって、前記3次元培養が膵前駆細胞の凝集体の浮遊培養であり、前記EGFファミリーに属する因子としてEGFを、前記FGFファミリーに属する因子としてFGF-7を、前記WntアゴニストとしてR-スポンジン1及びCHIR99021を含有する、工程、及び
(F)前記工程により培養した膵前駆細胞を凍結する工程を含む、凍結保存方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016091116 | 2016-04-28 | ||
JP2016091116 | 2016-04-28 | ||
PCT/JP2017/016728 WO2017188378A1 (ja) | 2016-04-28 | 2017-04-27 | 多能性幹細胞由来膵前駆細胞の純化法とその増幅法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017188378A1 JPWO2017188378A1 (ja) | 2019-04-04 |
JP7055740B2 true JP7055740B2 (ja) | 2022-04-18 |
Family
ID=60159764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018514702A Active JP7055740B2 (ja) | 2016-04-28 | 2017-04-27 | 多能性幹細胞由来膵前駆細胞の純化法とその増幅法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190136197A1 (ja) |
EP (1) | EP3450541A4 (ja) |
JP (1) | JP7055740B2 (ja) |
KR (1) | KR102257868B1 (ja) |
CN (1) | CN109415689A (ja) |
AU (1) | AU2017255099B2 (ja) |
CA (1) | CA3022365A1 (ja) |
EA (1) | EA201892447A1 (ja) |
IL (1) | IL262554A (ja) |
MX (1) | MX2018013175A (ja) |
SG (1) | SG11201809400UA (ja) |
TW (1) | TWI710636B (ja) |
WO (1) | WO2017188378A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020527956A (ja) * | 2017-07-21 | 2020-09-17 | センマ・セラピューティクス・インコーポレーテッド | 幹細胞由来の膵臓ベータ細胞の再凝集 |
EP3868870A4 (en) * | 2018-10-15 | 2022-10-19 | Evia Life Sciences Inc. | METHOD OF GENERATING STEM/PROGENIOR CELLS USING SMALL MOLECULAR COMPOUNDS FROM CELLS DERIVED FROM AN ENDODERMAL TISSUE OR ORGAN |
CN109749986B (zh) * | 2019-03-13 | 2021-04-02 | 武汉大学 | 一种由人多能干细胞分化获得胰腺前体细胞及胰岛β细胞的方法 |
CN113046299A (zh) * | 2021-03-19 | 2021-06-29 | 上海爱萨尔生物科技有限公司 | 一种诱导多能干细胞定向分化制备胰岛β细胞的添加剂 |
CN112961823B (zh) * | 2021-03-19 | 2024-01-23 | 上海爱萨尔生物科技有限公司 | 一种诱导多能干细胞定向分化制备胰岛β细胞的培养液 |
CN112980774B (zh) * | 2021-03-19 | 2022-04-01 | 上海爱萨尔生物科技有限公司 | 一种诱导多能干细胞定向分化制备胰岛β细胞的培养方法 |
CN113234664A (zh) * | 2021-05-11 | 2021-08-10 | 澳门大学 | 一种胰腺祖细胞的制备方法及其应用 |
CN115011544B (zh) * | 2022-05-30 | 2023-11-17 | 广州国家实验室 | 体外诱导获得胰岛δ细胞的方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100272695A1 (en) | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2015013653A1 (en) | 2013-07-26 | 2015-01-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Generating definitive endoderm and pancreatic progenitor cells |
WO2016021734A1 (ja) | 2014-08-04 | 2016-02-11 | 武田薬品工業株式会社 | 膵前駆細胞の増殖方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5579281A (en) | 1978-11-28 | 1980-06-14 | Nippon Oil Co Ltd | Rainnproof construction of floatinggroof tank |
JP6161603B2 (ja) * | 2012-05-25 | 2017-07-12 | 学校法人 埼玉医科大学 | 膵臓ホルモン産生細胞の生産方法及び膵臓ホルモン産生細胞、並びに分化誘導促進剤 |
JP2014161257A (ja) * | 2013-02-22 | 2014-09-08 | Univ Of Tokyo | 多能性幹細胞から膵ランゲルハンス島を製造する方法 |
JP6602288B2 (ja) * | 2013-04-03 | 2019-11-06 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 浮遊液中で内胚葉前駆細胞を培養するための方法および組成物 |
-
2017
- 2017-04-27 CA CA3022365A patent/CA3022365A1/en active Pending
- 2017-04-27 EP EP17789660.2A patent/EP3450541A4/en not_active Withdrawn
- 2017-04-27 AU AU2017255099A patent/AU2017255099B2/en not_active Ceased
- 2017-04-27 KR KR1020187034169A patent/KR102257868B1/ko active IP Right Grant
- 2017-04-27 TW TW106114087A patent/TWI710636B/zh not_active IP Right Cessation
- 2017-04-27 WO PCT/JP2017/016728 patent/WO2017188378A1/ja active Application Filing
- 2017-04-27 EA EA201892447A patent/EA201892447A1/ru unknown
- 2017-04-27 SG SG11201809400UA patent/SG11201809400UA/en unknown
- 2017-04-27 MX MX2018013175A patent/MX2018013175A/es unknown
- 2017-04-27 CN CN201780039853.8A patent/CN109415689A/zh active Pending
- 2017-04-27 US US16/096,855 patent/US20190136197A1/en not_active Abandoned
- 2017-04-27 JP JP2018514702A patent/JP7055740B2/ja active Active
-
2018
- 2018-10-24 IL IL262554A patent/IL262554A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100272695A1 (en) | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2015013653A1 (en) | 2013-07-26 | 2015-01-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Generating definitive endoderm and pancreatic progenitor cells |
WO2016021734A1 (ja) | 2014-08-04 | 2016-02-11 | 武田薬品工業株式会社 | 膵前駆細胞の増殖方法 |
Non-Patent Citations (3)
Title |
---|
Annals of Biomedical Engineering,2014年,Vol. 42, No. 7,pp.1357-1372 |
nature biotechnology,2014年,vol.32,no.11,p.1121-1133,ONLINE METHODS |
STEM CELLS AND DEVELOPMENT,2015年,vol.24,no.15,p.1766-1778 |
Also Published As
Publication number | Publication date |
---|---|
SG11201809400UA (en) | 2018-11-29 |
EP3450541A4 (en) | 2019-11-13 |
AU2017255099B2 (en) | 2021-07-15 |
TWI710636B (zh) | 2020-11-21 |
KR20180136544A (ko) | 2018-12-24 |
CA3022365A1 (en) | 2017-11-02 |
MX2018013175A (es) | 2019-02-21 |
AU2017255099A1 (en) | 2018-11-22 |
CN109415689A (zh) | 2019-03-01 |
KR102257868B1 (ko) | 2021-05-27 |
EP3450541A1 (en) | 2019-03-06 |
US20190136197A1 (en) | 2019-05-09 |
JPWO2017188378A1 (ja) | 2019-04-04 |
IL262554A (en) | 2018-12-31 |
EA201892447A1 (ru) | 2019-04-30 |
WO2017188378A1 (ja) | 2017-11-02 |
TW201800576A (zh) | 2018-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7055740B2 (ja) | 多能性幹細胞由来膵前駆細胞の純化法とその増幅法 | |
US10828335B2 (en) | Production of midbrain dopaminergic neurons and methods for the use thereof | |
JP7018875B2 (ja) | 多能性幹細胞からのヒト皮膚オルガノイドの誘導 | |
JP2018531027A6 (ja) | 多能性幹細胞からのヒト皮膚オルガノイドの誘導 | |
KR102210180B1 (ko) | 모양체 주연부형 구조체의 제조 방법 | |
KR20170092694A (ko) | 다능성 줄기세포로부터의 각막 상피 세포의 분화 유도 방법 | |
KR102318706B1 (ko) | 모양체 주연부-유사 구조체의 제조 방법 | |
CA2968655A1 (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
JP6694215B2 (ja) | 新規軟骨細胞誘導方法 | |
JP7248246B2 (ja) | 神経組織の保存方法 | |
US20220233646A1 (en) | Enhanced differentiation of beta cells | |
KR20200106930A (ko) | 다능성 줄기 세포로부터 장관 상피 세포로의 분화 유도 방법 | |
JP2016202172A (ja) | 疑似膵島の製造方法 | |
TW202026420A (zh) | 胰島素產生細胞 | |
WO2020203532A1 (ja) | 多能性幹細胞の製造方法 | |
WO2022168908A1 (ja) | 多能性幹細胞由来の陰窩-絨毛様構造を有する腸管細胞の製造方法及びその用途 | |
JP7328688B2 (ja) | 副甲状腺細胞の作製方法 | |
CN116391028A (zh) | 促熟剂 | |
JP2023503302A (ja) | スピン凝集した神経系マイクロスフェアおよびその応用 | |
US11857697B2 (en) | Compositions and methods for obtaining 3-dimensional lung-like epithelium and related uses thereof | |
WO2022172960A1 (ja) | 成熟化剤 | |
TW201945536A (zh) | 水凝膠膠囊 | |
Correia | Microencapsulation technology: a powerful tool for human embryonic stem cells expansion and cryopreservation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200309 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210421 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220124 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220201 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220208 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220406 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7055740 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |